Decisive reversal of lethal coronavirus disease 2019 in senescent hamster by synchronic antiviral and immunoregulatory intervention.

MedComm (2020)

State Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, NMPA Key Laboratory for Research and Evaluation of Infectious Disease Diagnostic Technology, School of Life Sciences & School of Public Health Xiamen University Xiamen Fujian China.

Published: August 2024

The poor prognosis observed in elderly individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a serious clinical burden and the underlying mechanism is unclear, which necessities detailed investigation of disease characteristics and research for efficient countermeasures. To simulate lethal coronavirus disease 2019 (COVID-19) in senescent human patients, 80-week-old male hamsters are intranasally inoculated with different doses of SARS-CoV-2 Omicron BA.5 variant. Exposure to a low dose of the Omicron BA.5 variant results in early activation of the innate immune response, followed by rapid viral clearance and minimal lung damage. However, a high dose of BA.5 results in impaired interferon signaling, cytokine storm, uncontrolled viral replication, and severe lung injury. To decrease viral load and reverse the deterioration of COVID-19, a new bio-mimic decoy called CoVR-MV is used as a preventive or therapeutic agent. Administration of CoVR-MV as a preventive or therapeutic intervention in the early stages of infection can effectively suppress viral load, regulate the immune response, and rescue animals from death and critical illness. These findings underscore the risk associated with SARS-CoV-2 Omicron BA.5 exposure in senescent hamsters and highlight the importance of early intervention to prevent disease progression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258460PMC
http://dx.doi.org/10.1002/mco2.642DOI Listing

Publication Analysis

Top Keywords

omicron ba5
12
lethal coronavirus
8
coronavirus disease
8
disease 2019
8
sars-cov-2 omicron
8
ba5 variant
8
immune response
8
viral load
8
covr-mv preventive
8
preventive therapeutic
8

Similar Publications

Article Synopsis
  • - SARS-CoV-2 is still a major cause of death in North America, and this study examines how methotrexate and tumor necrosis factor inhibitors (TNFi) affect vaccine responses in patients with immune-mediated inflammatory diseases (IMID).
  • - Researchers collected and analyzed serum samples from 479 adults with conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) across Canada to evaluate neutralization responses to COVID-19 vaccination.
  • - The results indicated that both methotrexate and TNFi independently reduced the ability to neutralize the virus, underscoring the need for careful vaccination strategies as COVID-19 remains widespread.
View Article and Find Full Text PDF

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.

BMC Infect Dis

August 2024

Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.

Background: The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatment affected both PCC and health-related quality of life.

Methods: This retrospective cohort study enrolled 2,524 adults aged 18 years and older who were eligible for nirmatrelvir/ritonavir between July 14 to November 14, 2022.

View Article and Find Full Text PDF
Article Synopsis
  • Although the Omicron variant of SARS-CoV-2 has many mutations, the backbone of its spike protein remains largely the same, providing a stable target for vaccine design.
  • Researchers created several subunit vaccines using this stable backbone along with various receptor-binding domains from different SARS-CoV-2 variants to test their immune response capabilities.
  • The S-6P-Delta-RBD vaccine showed strong effectiveness, generating broad neutralizing antibodies and offering complete protection against severe outcomes from Delta and Omicron infections in mice, indicating its potential as a universal COVID-19 vaccine.
View Article and Find Full Text PDF

Background: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19? Therefore, we investigated the effectiveness of Paxlovid™ on reducing the incidence of pneumonia, hospitalization, and mortality in a cohort of COVID-19 positive adult patients from northeast Mexico.

Methods: A retrospective cohort study of COVID-19 positive adult patients from Nuevo Leon, Mexico from December 2020 to May 2023 (after Omicron BA-5 circulation) was performed.

View Article and Find Full Text PDF

The emergence of the variant of concern Omicron (B.1.1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!